Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Quickcomparison

Dose Range CJC-1295 (No DAC) 100–300 mcg Ipamorelin Frequency Once daily Multiple times daily Administration Subcutaneous injection Cycle Length 8-12 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy

This comparison does not assign a generated winner or score.

  • Dose Range
  • CJC-1295 (No DAC)
  • 100–300 mcg
  • Ipamorelin
  • Frequency
  • Once daily
  • Multiple times daily
  • Administration
  • Subcutaneous injection
  • Cycle Length
  • 8-12 weeks
  • Onset Speed
  • Moderate (1-2 weeks)
  • Evidence Level
  • Moderate human trials (Phase 1-2)
  • Efficacy
More references

Related material